{"id":"https://openalex.org/W2958966890","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","title":"TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).","display_name":"TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2958966890","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","mag":"2958966890"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.e19052","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058586595","display_name":"Donald L. Patrick","orcid":"https://orcid.org/0000-0003-0756-0492","observed_orcids":["https://orcid.org/0000-0003-0756-0492"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Donald L. Patrick","raw_affiliation_strings":["University of Washington Department of Health Services, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington Department of Health Services, Seattle, WA;","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076430463","display_name":"Karen Chung","orcid":"https://orcid.org/0000-0003-4170-8390","observed_orcids":["https://orcid.org/0000-0003-4170-8390"]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen C. Chung","raw_affiliation_strings":["Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109284805","display_name":"Yeonhee Kim","orcid":"https://orcid.org/0009-0001-2563-5497","observed_orcids":["https://orcid.org/0009-0001-2563-5497"]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yeonhee Kim","raw_affiliation_strings":["Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039487484","display_name":"Jacob Garcia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Garcia","raw_affiliation_strings":["Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108654277","display_name":"Christine Dehner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Dehner","raw_affiliation_strings":["Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, Inc., a Celgene Company, Seattle, WA;","institution_ids":["https://openalex.org/I4405280080"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G. Maloney","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA;","institution_ids":["https://openalex.org/I4210089486"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"e19052","last_page":"e19052"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10178","display_name":"Cancer survivorship and care","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.004600000102072954,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-diffuse-large-b-cell-lymphoma","display_name":"relapsed/refractory diffuse large B-cell lymphoma","score":0.9829999804496765},{"id":"https://openalex.org/keywords/lisocabtagene-maraleucel","display_name":"lisocabtagene maraleucel","score":0.9819999933242798},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/anti-cd19-antibody","display_name":"anti-CD19","score":0.8999999761581421},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.9980000257492065},{"id":"https://openalex.org/keywords/symptom-burden","display_name":"symptom burden","score":0.7850000262260437},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.7179999947547913},{"id":"https://openalex.org/keywords/pain","display_name":"pain","score":0.9039999842643738},{"id":"https://openalex.org/keywords/global-health-status","display_name":"global health status","score":0.7289999723434448},{"id":"https://openalex.org/keywords/functional-status","display_name":"functional status","score":0.7139999866485596},{"id":"https://openalex.org/keywords/eortc-qlq-c30","display_name":"EORTC QLQ-C30","score":0.9279999732971191},{"id":"https://openalex.org/keywords/lymphodepletion","display_name":"lymphocyte depletion","score":0.7990000247955322}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8651871681213379},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6228832602500916},{"id":"https://openalex.org/C2779951463","wikidata":"https://www.wikidata.org/wiki/Q7268788","display_name":"Quality of life (healthcare)","level":2,"score":0.5313376188278198},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.4745170474052429},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.47208496928215027},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.4334900379180908},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.42947423458099365},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3967559337615967},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3672565519809723},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3579665720462799},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.24235254526138306},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.e19052","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.e19052","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3157319952","https://openalex.org/W2990662760","https://openalex.org/W4399281064","https://openalex.org/W4297016769","https://openalex.org/W3213081702","https://openalex.org/W2953397734","https://openalex.org/W4310112316","https://openalex.org/W4379979773","https://openalex.org/W4281868077","https://openalex.org/W4417016174"],"abstract_inverted_index":{"e19052":[0],"Background:":[1],"R/R":[2,35,72,78],"DLBCL":[3,36,79],"is":[4,10],"associated":[5],"with":[6,34,43,45,71,77,246],"decreased":[7],"HRQL.":[8],"Liso-cel":[9],"an":[11],"investigational,":[12],"anti-CD19":[13],"CAR":[14,25],"T":[15,26],"cell":[16],"product":[17],"administered":[18,98],"as":[19],"a":[20,90],"defined":[21],"composition":[22],"of":[23,48,65,210],"CD4+/CD8+":[24],"cells.":[27],"In":[28,237],"the":[29,63],"ongoing":[30],"TRANSCEND":[31],"study,":[32],"pts":[33,70,76,154,212],"achieved":[37],"high":[38],"best":[39],"overall":[40],"response":[41],"rates":[42,47],"liso-cel,":[44],"low":[46],"severe":[49],"cytokine":[50],"release":[51],"syndrome":[52],"and":[53,67,106,109,112,115,128,176,178,192,231,240],"neurological":[54],"events":[55],"(Abramson":[56],"et":[57],"al,":[58],"ASCO":[59],"2018).":[60],"We":[61],"examined":[62],"impact":[64],"Sx":[66,111,138,166],"HRQL":[68,241],"in":[69,126,137,205,217,243,250],"DLBCL.":[73],"Methods:":[74],"Eligible":[75],"(\u226518":[80],"yr,":[81],"\u22652":[82],"prior":[83],"therapy":[84],"lines)":[85],"received":[86],"lymphodepletion":[87],"followed":[88,200],"by":[89,201],"single":[91],"liso-cel":[92,256],"infusion.":[93,257],"The":[94,208],"EORTC":[95],"QLQ-C30":[96],"was":[97],"at":[99,197],"baseline":[100],"(BL),":[101],"day":[102],"29":[103],"(mo":[104],"1),":[105],"mo":[107,186,198,206,221,254],"2":[108],"3.":[110],"functional":[113,127],"scales":[114],"gIobal":[116],"health":[117,174,233],"status":[118,175],"were":[119,140,161],"analyzed.":[120],"Increases":[121],"from":[122,133,147,185],"BL":[123,134,184,204],"\u226510":[124,135],"points":[125,136],"QL":[129],"scores":[130,139,167,181,195],"or":[131],"decreases":[132],"considered":[141],"clinically":[142,214,247],"meaningful":[143,215,248],"improvement.":[144],"Scores":[145],"range":[146],"0-100.":[148],"Results:":[149],"At":[150],"data":[151],"cutoff,":[152],"87/127":[153],"(mean":[155],"[SD]":[156],"age":[157],"62":[158],"[11]":[159],"yr)":[160],"evaluable":[162],"(BL+\u22651":[163],"post-BL":[164],"assessment).":[165],"generally":[168],"improved":[169,182,242],"postinfusion":[170,222],"(Table).":[171],"Mean":[172],"global":[173,232],"emotional":[177],"cognitive":[179],"function":[180,194],"vs":[183,203],"1-3":[187],"postinfusion,":[188],"while":[189],"physical,":[190],"role,":[191],"social":[193],"declined":[196],"1,":[199],"improvements":[202,249],"2-3.":[207],"proportion":[209],"surviving":[211,244],"achieving":[213],"improvement":[216],"key":[218,251],"domains":[219],"3":[220],"were:":[223],"fatigue,":[224],"50%;":[225],"pain,":[226],"51%;":[227],"physical":[228],"function,":[229],"22%;":[230],"status,":[234],"41%.":[235],"Conclusions:":[236],"TRANSCEND,":[238],"symptoms":[239],"pts,":[245],"domains,":[252],"2-3":[253],"after":[255],"Clinical":[258],"trial":[259],"information:":[260],"NCT02631044.":[261],"[Table:":[262],"see":[263],"text]":[264]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-09-21T07:43:02.447757","created_date":"2019-07-23T00:00:00"}